Atorvastatin in Myeloma
1 other identifier
interventional
N/A
1 country
1
Brief Summary
The purpose of this trial is to study the effects of a medication already widely used to treat cardiovascular disease and diabetes, in reducing the progression of myeloma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 13, 2005
CompletedFirst Posted
Study publicly available on registry
September 14, 2005
CompletedOctober 11, 2006
September 1, 2005
September 13, 2005
October 10, 2006
Conditions
Interventions
Eligibility Criteria
You may qualify if:
- Myeloma in remission
You may not qualify if:
- Adverse events (AEs) to statin, already on a statin, or contraindication to statin
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Bayside Healthlead
Study Sites (1)
Alfred Hospital
Melbourne, Victoria, 3181, Australia
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Andrew Spencer, MBChB, FRACP, PhD
The Alfred
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER GOV
Study Record Dates
First Submitted
September 13, 2005
First Posted
September 14, 2005
Last Updated
October 11, 2006
Record last verified: 2005-09